0
0

Studying Suboxone Act

1/3/2024, 5:45 PM

Summary of Bill HR 4053

Bill 118 HR 4053, also known as the Studying Suboxone Act, is a piece of legislation introduced in the US Congress. The purpose of this bill is to authorize the Department of Health and Human Services to conduct a study on the effectiveness of Suboxone in treating opioid addiction.

Suboxone is a medication commonly used in medication-assisted treatment for opioid addiction. It contains a combination of buprenorphine and naloxone, which work together to reduce cravings and withdrawal symptoms in individuals struggling with opioid dependence.

The Studying Suboxone Act aims to gather data and research on the use of Suboxone in treating opioid addiction, including its effectiveness, safety, and potential side effects. This information will be crucial in informing policymakers and healthcare providers on the best practices for treating opioid addiction and reducing the harm caused by the opioid epidemic. Overall, Bill 118 HR 4053 seeks to improve our understanding of Suboxone as a treatment option for opioid addiction and to ultimately improve outcomes for individuals struggling with substance use disorders. It highlights the importance of evidence-based research in addressing the ongoing public health crisis of opioid addiction in the United States.

Current Status of Bill HR 4053

Bill HR 4053 is currently in the status of Bill Introduced since June 13, 2023. Bill HR 4053 was introduced during Congress 118 and was introduced to the House on June 13, 2023.  Bill HR 4053's most recent activity was Referred to the Subcommittee on Health. as of June 16, 2023

Bipartisan Support of Bill HR 4053

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
6
Democrat Cosponsors
2
Republican Cosponsors
4
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 4053

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 4053

Studying Suboxone Act
Studying Suboxone Act
To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.

Comments